Early testing indicates that the mutations in the Omicron variant of coronavirus may hamper the ability of Regeneron’s antibody drug to treat Covid-19, the company said, indicating that some therapies may have to be adapted to tackle the virus’s latest evolution.
再生元(Regeneron)表示，早期试验表明，Omicron变种上的突变可能会阻碍该公司的抗体药物治疗新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）的能力。这表明可能必须调整某些疗法以应对新冠病毒的最新进化。
The findings are a first indication that treatments developed to tackle Covid-19 may have lost effectiveness as the virus evolves. “The individual mutations present in the Omicron variant indicate that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity,” Regeneron said on Tuesday.
这些发现是表明随着病毒的进化、为应对COVID-19而开发的疗法可能失去效力的首个迹象。“Omicron存在的个别突变表明，疫苗诱导和单克隆抗体传递的免疫反应的中和活性都可能降低，”再生元周二表示。